Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)
Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy. Anti-integrin αvβ6 antibody titre shows promise in predicting response to carotegrast methyl. Faecal calprotectin may serve as a non-invasive surrogate for evaluating endoscopic healing.
Authors
- Hiroshi Nakase (ORCID: https://orcid.org/0000-0003-2848-6586)
- Fumihito Hirai (ORCID: https://orcid.org/0000-0002-5493-5675)
- Kenji Watanabe (ORCID: https://orcid.org/0000-0002-3781-4724)
- Mamoru Watanabe (ORCID: https://orcid.org/0000-0002-5475-9544)
- G Yamazaki
- Taku Kobayashi (ORCID: https://orcid.org/0000-0002-2073-4234)
- Masayuki Saruta (ORCID: https://orcid.org/0000-0001-8172-3240)
- Katsuyoshi Matsuoka (ORCID: https://orcid.org/0000-0002-2950-7660)
- Ryota Hokari (ORCID: https://orcid.org/0000-0002-8511-2540)
- Takahiro Suzuki (ORCID: https://orcid.org/0000-0002-9768-0780)
- Toshifumi Hibi
- Tadakazu Hisamatsu
Institutions
- Jikei University School of Medicine (JP)
- Toho University (JP)
- Sapporo Medical University (JP)
- Kyorin University (JP)
- Juntendo University (JP)
- Fukuoka University Hospital (JP)
- Kissei Pharmaceutical (Japan) (JP)
- Toho University Medical Center Sakura Hospital (JP)
- EA Pharma (Japan) (JP)
- Kitasato Institute Hospital (JP)
- University of Toyama (JP)
- National Defense Medical College (JP)
- Kitasato University (JP)
Publication Details
- Journal
- Journal of Gastroenterology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1007/s00535-025-02299-9
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- EA Pharma Co., Ltd.
- Kissei